Symbol | Exchange | Currency |
|---|
C4 Therapeutics (CCCC)announces the closing of an underwritten public offering of 4.89M shares at a price of$37/share for aggregate gross proceeds of $180.8M.The offering...
– CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin's Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins ––...
C4 Therapeutics (CCCC) announced that it is offering to sell 4.25 million shares of its common stock at $37 per share. Shares gained 1.2% to close at $38.12 on June 17.Founded in...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Sell | Buy |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Buy | Neutral | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,450.00 | 2,461.10 | 2,446.00 | +7.5 | +0.31% | 1.07M | NASDAQ | |||
| 343.18 | 344.90 | 341.79 | +2.59 | +0.76% | 12.33M | NASDAQ | |||
| 56.70 | 58.76 | 55.66 | -1.60 | -2.74% | 80.35M | NYSE | |||
| 218.38 | 219.58 | 215.56 | +3.52 | +1.64% | 13.49M | NYSE | |||
| 779.32 | 809.63 | 772.95 | -24.24 | -3.02% | 1.11M | NASDAQ | |||
| 232.97 | 239.37 | 230.42 | +15.87 | +7.31% | 12.29M | NYSE | |||
| 229.93 | 230.04 | 226.67 | +3.92 | +1.73% | 2.86M | NASDAQ | |||
| 311.81 | 324.54 | 310.85 | -9.89 | -3.07% | 367.33K | NASDAQ | |||
| 2,545.60 | 2,550.70 | 2,539.20 | +16.4 | +0.65% | 946.66K | NASDAQ | |||
| 12.68 | 13.33 | 12.64 | -0.46 | -3.50% | 22.16M | NYSE | |||
| 28.79 | 28.84 | 28.61 | +0.14 | +0.49% | 35.88M | NYSE | |||
| 14.39 | 14.41 | 12.61 | +0.78 | +5.73% | 174.20M | NASDAQ | |||
| 151.55 | 156.59 | 149.54 | -3.10 | -2.00% | 1.19M | NYSE | |||
| 194.77 | 195.71 | 190.45 | +5.60 | +2.96% | 4.41M | NASDAQ | |||
| 163.37 | 164.20 | 162.80 | +0.74 | +0.46% | 4.55M | NYSE |
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.